Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia
| العنوان: | Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia |
|---|---|
| المؤلفون: | Umur A Pehlivan, Emel Gürkan, İbrahim H Açar, Yunus K Bıçakcı |
| المصدر: | Journal of Oncology Pharmacy Practice. 29:246-251 |
| بيانات النشر: | SAGE Publications, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Adult, Central Nervous System, Neutropenia, Oncology, Humans, Neurotoxicity Syndromes, Pharmacology (medical), Arabinonucleosides, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
| الوصف: | Introduction Nelarabine, a prodrug of arabinosylguanine has lineage-specific toxicity for T lymphoblasts and is used to treat refractory or relapsed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma patients. The most commonly observed adverse effects associated with nelarabine are mainly hematological, i.e. neutropenia, anemia, and thrombocytopenia. Additionally, neurological, and gastrointestinal toxicities have been reported. Central nervous system neurotoxicity associated with nelarabine is very rare. Case description A 37-year-old man patient diagnosed with T-cell acute lymphoblastic leukemia had experienced generalized tonic-clonic seizure which lasted for a few seconds and upper extremity weakness after three weeks of the nelarabine infusion. Computed tomography and magnetic resonance imaging have shown periventricular and nucleus caudatus abnormalities. Radiological findings suggested toxic leukoencephalopathy and acute infarct of right nucleus caudatus. Management and outcome After high-dose steroids, intravenous immunoglobulin, and support treatment, his neurologic symptoms disappeared except for mild peroral numbness. However, radiological sequelae persisted despite clinical improvement. Conclusion Physicians involved in the care of these patients who use nelarabine should be aware of the fact that cerebral toxicity of the nelarabine may occur especially in the presence of predisposing factors. It is crucial to monitor closely those patients receiving nelarabine and also those who have additional predisposing factors for neurotoxicity. |
| تدمد: | 1477-092X 1078-1552 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc7c337ed4659094f0883f888da49fa https://doi.org/10.1177/10781552221102591 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....efc7c337ed4659094f0883f888da49fa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477092X 10781552 |
|---|